Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Grant_Pickering
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
gptkb:PCV20_(pneumococcal_conjugate_vaccine)
|
| gptkbp:focusesOn |
vaccine development
|
| gptkbp:formerName |
gptkb:SutroVax
|
| gptkbp:foundedYear |
2013
|
| gptkbp:hasConnection |
gptkb:PCV24
gptkb:PCV20 other vaccine candidates |
| gptkbp:headquartersLocation |
gptkb:San_Carlos,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Vaxcyte
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:NASDAQ_Global_Select_Market
|
| gptkbp:numberOfEmployees |
over 200
|
| gptkbp:publiclyTraded |
gptkb:NASDAQ
|
| gptkbp:specializesIn |
conjugate vaccines
protein-based vaccines |
| gptkbp:stockSymbol |
gptkb:PCVX
|
| gptkbp:technology |
cell-free protein synthesis
|
| gptkbp:website |
https://www.vaxcyte.com/
|
| gptkbp:bfsParent |
gptkb:Osage_University_Partners
|
| gptkbp:bfsLayer |
6
|